

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Cryofocus Medtech (Shanghai) Co., Ltd.**

**康豐生物科技(上海)股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 6922)**

## **VOLUNTARY ANNOUNCEMENT**

### **NMPA APPROVAL FOR DISPOSABLE INTRACARDIAC MAPPING CATHETER AND ADJUSTABLE CURVED GUIDE CATHETER OF ATRIAL FIBRILLATION CRYOABLATION SYSTEM**

Reference is made to the announcement of Cryofocus Medtech (Shanghai) Co., Ltd. (the “**Company**”, together with its subsidiaries, the “**Group**”) dated December 5, 2023 in relation to its Atrial Fibrillation Cryoablation System (心臟冷凍消融系統) (“**AF Cryoablation System**”). This announcement is made by the Company on a voluntary basis to provide shareholders of the Company and potential investors with updated information in relation to the latest business and new product development of the Group.

The Company is pleased to announce that, following the grant of approval by the National Medical Products Administration of the People's Republic of China (國家藥品監督管理局) (the “**NMPA**”) to the two key components of the AF Cryoablation System, namely, the cryoablation equipment (冷凍消融設備) and the balloon cryoablation catheter (球囊型冷凍消融導管) (formerly known as AF cryoablation catheter (房顫冷凍消融導管)) on December 4, 2023, the two remaining components of the AF Cryoablation System, namely, the disposable intracardiac mapping catheter (一次性使用心內標測導管) (formerly known as an intracardiac mapping catheter (心內標測導管)) and the adjustable curved guide catheter (可調彎導引導管) (formerly known as a steerable sheath (可調彎鞘)), were granted approval by the NMPA on December 4, 2023 and December 7, 2023, respectively. Following all such NMPA approvals, the Company has obtained the marketing approval for the AF Cryoablation System from the NMPA.

The AF Cryoablation System, a self-developed cryoablation system consisting of the four aforementioned components, is the first cardiac liquid nitrogen cryoballoon ablation product. The AF Cryoablation System will be used for the treatment of drug-refractory recurrent symptomatic paroxysmal atrial fibrillation.

**THE COMPANY CANNOT GUARANTEE THE FUTURE PROSPECTS OF THE AF CRYOABLATION SYSTEM. SHAREHOLDERS OF THE COMPANY AND THE POTENTIAL INVESTORS ARE ADVISED TO EXERCISE DUE CARE WHEN DEALING IN THE SHARES OF THE COMPANY.**

By Order of the Board  
**Cryofocus Medtech (Shanghai) Co., Ltd.**  
**Mr. LI Kejian**  
*Chairman of the Board*

Hong Kong, December 11, 2023

*As at the date of this announcement, the Board comprises Mr. LI Kejian, Mr. ZHU Jun and Mr. LIU Wei as executive Directors, Mr. LV Shiwen and Mr. ZHAO Chunsheng as non-executive Directors, and Dr. GAO Dayong, Mr. LIANG Hsien Tse Joseph, Dr. QIN Zheng and Dr. HU Henan as independent non-executive Directors.*